Anticoagulation UK provides information, tools and resources for patients and healthcare professionals to aid knowledge and understanding of the conditions requiring anticoagulation including all available anticoagulation therapy option
Please review all the categories below to find the information you require:
Anticoagulants are a type of drug that reduce the body's ability to form clots in the blood. Although they are sometimes called blood thinners, they do not actually thin the blood but interfere with the clotting process and therefore help to stop clots forming in the veins.
This type of medicine will not dissolve clots that already have formed, although it will help to stop an existing clot from getting larger.
Post-thrombotic syndrome (PTS)
Post thrombotic syndrome is a complication of deep vein thrombosis affecting around 20-40% of people with a history of DVT.
If you have had a deep vein thrombosis (DVT), usually in the leg, the blood clot in the vein of your calf can divert the flow of blood to other veins, causing an increase in pressure on the vein walls which can damage the valves that work to keep the blood circulating in the leg.
PTS may develop within six months and up to two years after an initial DVT. People who have a recurrence of DVT will be at heightened risk of the condition.
Heart Valves and Heart Valve Disease
The heart is a sophisticated pump that keeps blood moving around the body. It carries oxygen and nutrients to all parts of the body and carries away unwanted waste products including carbon dioxide.
Within the heart, there are four chambers. The two upper chambers are the Atria and the larger lower chambers are known as the Ventricles. As your heart muscle contracts, it pushes blood through your heart. With each contraction or heartbeat, deoxygenated blood flows into the right side of the heart, which pumps it to the lungs to pick up oxygen. The oxygenated blood then returns to the left side and is then transported by the circulatory system to the tissues of the body.
A stroke is a serious medical condition that occurs when the blood supply to part of the brain is cut off. It can affect our bodily functions, thought processing, ability to learn, communication and emotions.
There are two types of stroke. When a blood clot blocks in a blood vessel in the brain this is called an ischemic stroke or bleeding from a ruptured vessel in the brain this is called a haemorrhagic stroke.
A stroke is a medical emergency. If you think someone is having a stroke dial 999 immediately.
Thrombosis & Genetic Disorders
Thrombophilia refers to a group of conditions where the blood clots more easily than normal. This can lead to unwanted blood clots forming within blood vessels. These blood clots can cause problems such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
Thrombophilia occurs if the normal balance of the clotting system is upset. There may be too much of a clotting factor, or too little of a substance that opposes clotting.
Thrombophilia can cause unwanted blood clots. This does not mean that you will develop a blood clot, but that you have a higher risk than normal of having clots. The extra risk will depend on the type of thrombophilia that you have.
Anticoagulants and monitoring
There are currently five main oral anticoagulants.
Apixaban (Eliquis), Dabigatran (Pradaxa), Edoxaban (Lixiana), Rivaroxaban (Xarelto) and Warfarin.
Apixaban, Dabigatran. Edoxaban and Rivaroxaban are known as Direct Oral Anticoagulants (DOACS) sometimes also called Novel Oral Anticoagulants (NOACS).
Warfarin is known as a Vitamin K Antagonist (VKA).
NHS England has introduced guidelines that set out which over the counter items should not be prescribed in primary care
In the year prior to June 2017, the NHS spent approximately £569 million on prescriptions for medicines that can be purchased over the counter from a pharmacy and other outlets such as supermarkets. Over the counter products currently prescribed include cough mixture and cold treatments, painkillers, eye drops, laxatives and sun cream lotions.
NHS England estimate savings of around £100 million a year (2) by cutting such prescriptions for minor, short term conditions, many of which will cure themselves or cause no long term effect on health.
DEVELOPING OPTIMAL STANDARDS OF CARE FOR THE PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM (VTE): CONSENSUS STATEMENT
During 2018 Anticoagulation UK worked in partnership with the Bristol Myers Squibb Pfizer Alliance to bring together a group of eminent experts to identify actions for improvements in the management of patients at risk of recurrent venous thromboembolism (VTE). The aim of the meeting was for attendees to agree recommendations for the optimal standard of care for patients at risk of recurrent VTE. The consensus statement is the outcome from this meeting.